Roche has turned to its incubation partners at Versant Venture’s Inception Sciences to create a virtual biotech which will set out to spawn new therapies that can repair the damaged nerves of patients with multiple sclerosis.
Following a popular model for drug R&D set up by several venture groups over the last few years, Roche will fund the work done by the virtual team at Inception 5, with Versant bankrolling the equity investments needed and Roche paying the research tab. Any small molecules that promise to spur remyelination–protecting the damaged nerve sheaths associated with MS–can be snapped up by Roche under an option arrangement.
The deal follows up on a similar pact the pharma giant set up on Inception 3 back in the fall of 2012 for hearing loss. Inception is run by Amira co-founder Peppi Prasit. His team will pursue small molecules for remyelination, a strategy for repairing the nerve damage caused by MS that has been attracting some attention recently. Acorda and Biogen Idec are both at work in this field and clinicaltrials.gov lists several ongoing studies related to remyelination.
Unlike some of the other majors, Roche is still very active in the neuroscience field, with a dozen neuroscience programs in the pipeline under Luca Santarelli.
This article has been extracted from http://www.fiercebiotech.com, please click on this link to read the article in full http://www.fiercebiotech.com/story/roche-partners-versant-new-build-sell-biotech-ms/2014-06-23
Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:
ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.
With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.